$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
释倍灵用途和效果
2025-10-19 11:44:20
Check Details
Glofitamab对I-IIA级、转化型滤泡性淋巴瘤具有较好的抗肿瘤活性
2025-10-19 11:44:20
Check Details
利妥昔单抗注射液功效与作用
2025-10-19 11:44:20
Check Details
利妥昔单抗注射液进入医保了吗?
2025-10-19 11:44:20
Check Details
利妥昔单抗治疗淋巴瘤多久见效?
2025-10-19 11:44:20
Check Details
利妥昔单抗在医保范围内吗?
2025-10-19 11:44:20
Check Details
利妥昔单抗注射液价格
2025-10-19 11:44:20
Check Details
利妥昔单抗多久打一次?
2025-10-19 11:44:20
Check Details
利妥昔单抗注射液医保可以报销吗?
2025-10-19 11:44:20
Check Details
利妥昔单抗注射液在哪买的到?
2025-10-19 11:44:20
Check Details
非共价BTK抑制剂LOXO-305在复发或难治性B细胞恶性肿瘤中的应用
2025-10-19 11:44:20
Check Details
2b期临床试验证实了厄布利塞在惰性淋巴瘤中的活性和安全性
2025-10-19 11:44:20
Check Details
1
2
...
1258
1259
1260
1261
1262
1263
1264
...
4162
4163
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Tucatinib Plus Trastuzumab and Pertuzumab Maintenance in HER2-Positive Advanced Breast Cancer: HER2CLIMB-05 Median PFS 24.9 Months
2
Zenocutuzumab (Bizengri) for NRG1 Fusion Solid Tumors: HER2×HER3 Bispecific, 750mg Q2W, NSCLC/Pancreas/Cholangiocarcinoma
3
Pemigatinib for FGFR2 Cholangiocarcinoma and FGFR1 Hematologic Use: First-Line Data, 21-Day Dosing, Phosphate and Ocular Management
4
Dabrafenib (Tafinlar) Complete Guide: Indications, Dosing, Combination Therapy and Safety
5
Binimetinib plus Encorafenib for BRAF‑Mutant Melanoma
6
Adagrasib (Krazati) for KRAS G12C: NSCLC Dosing, Titration, and CRC Regulatory Update
7
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
8
Enzalutamide for Prostate Cancer: Managing Fatigue, Dizziness, Hypertension, and Serious Neurocardiovascular Risks
9
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks
10
Acoramidis for ATTR-CM: Disease Progression Is Not Equivalent to Drug Resistance
11
Lorlatinib Contraindications and Safety Warnings: Six Key Risks to Monitor
12
Dacomitinib for EGFR-Mutant NSCLC: Dosing, Switching, and Safety Profile